Tuesday, 5 September 2023
Cannabis Stock News: TILT Holdings (NEO: TILT) (OTC: TLLTF), Shinnecock Nation and PowerFund Partners Finalize Change in Partnership of Little Beach Harvest Joint Venture
Cannabis Stock News: TILT Holdings (NEO: TILT) (OTC: TLLTF), Shinnecock Nation and PowerFund Partners Finalize Change in Partnership of Little Beach Harvest Joint Venture: Cannabis Stock News: TILT Holdings (NEO: TILT) (OTC: TLLTF), Shinnecock Nation and PowerFund Partners Finalize Change in Partnership of Little Beach Harvest Joint Venture
Cannabis Stock News: MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) Completes Sale of Vacant Land for Cash Proceeds of $1.9 million
Cannabis Stock News: MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) Completes Sale of Vacant Land for Cash Proceeds of $1.9 million: Cannabis Stock News: MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) Completes Sale of Vacant Land for Cash Proceeds of $1.9 million
Cannabis Stock News: Curaleaf (CSE: CURA) (OTCQX: CURLF) Expands Brand Portfolio With Launch of Zero Proof ™ Cannabis-Infused Drinkables
Cannabis Stock News: Curaleaf (CSE: CURA) (OTCQX: CURLF) Expands Brand Portfolio With Launch of Zero Proof ™ Cannabis-Infused Drinkables: Cannabis Stock News: Curaleaf (CSE: CURA) (OTCQX: CURLF) Expands Brand Portfolio With Launch of Zero Proof ™ Cannabis-Infused Drinkables
Friday, 1 September 2023
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move: (OTC: $PSYC), (OTCQB: $DBCCF), (OTCQB: $INNPF), (OTCQB: $MEDIF) and (NASDAQ: $CGC)
Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move: (OTC: $PSYC), (OTCQB: $DBCCF), (OTCQB: $INNPF),
(OTCQB: $MEDIF) and (NASDAQ: $CGC)
September 1, 2023 (Investorideas.com
Newswire), investorideas.com, a global news
source covering leading sectors including marijuana and hemp stocks and its potcast site
release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2023/090123-Cannabis.mp3
Read this in full at https://www.investorideas.com/news/2023/cannabis-potcasts/09011PSYC-DBCCF-INNPF-MEDIF-CGC.asp
Hear Investor ideas
cannabis potcast on iTunes
Hear the investor
ideas potcast on Spotify
Today’s podcast overview/transcript:
In today’s podcast we go over a few
public company announcements, the potential for cannabis rescheduling in the
U.S. as well as a frank discussion on cannabis studies and drug studies in
general.
PSYC
Corporation (OTC:
PSYC), parent company to Spotlight Media Corporation, announced the Company, through its wholly
owned subsidiary, Spotlight Media Corporation, has completed the acquisition of
the Stock Day Media platform from La Jolla Media,
LLC.
The deal, which is effective September 1,
2023, is valued at $500K and will be satisfied by the Company through a
combination of cash and stock distributions over the course of the next 12
months and contingent upon the achievement of specific net revenue targets
mutually established between the Company and Stock Day Media.
The acquisition follows the formation of a
strategic partnership between the Company and Target Media that was announced on August 29,
2023 and which, according to the Company, played a strategic role in providing
the Company with the initial financing required to execute this acquisition.
Founded in 2013, Stock Day Media has become
one of the fastest growing media outlets for Nano-Cap and Micro-Cap companies.
It educates investors while simultaneously working with penny stock and OTC companies,
providing transparency and clarification of under-valued, under-sold Micro-Cap
stocks of the market. Stock Day Media provides companies with customised
solutions to their news distribution in both national and international media
outlets.
The Stock Day Media website contains over
500 hours of resourceful digital content that includes approximately 1,500
podcast episodes published to Audioboom and an estimated 2,000 podcast episodes
published to its website.
The Company believes there may be an opportunity
to leverage the respective service offerings and brand authorities provided by
Stock Day Media along with its existing investor awareness-focused platforms
such as Technical 420, On the Bids, and Mushroom Stocks to increase its market
share within the investor awareness and public relations sectors and to develop
this arm of its business operations into a more prominent revenue driver for
PSYC.
“We are at a stage in the evolution of PSYC
where monetizing our assets and developing a solid and steady revenue model
that is pragmatically capable of contributing to our objective of
reconstructing our balance sheet is of paramount importance,” said PSYC CEO,
David Flores.
“Over the past 3 plus years, I have had the
privilege of working with Everett Jolly and the amazing Stock Day Media team
and have witnessed firsthand the incredible value their platform can deliver to
companies in the public arena. I believe that integrating their platform
beneath the evolving PSYC umbrella of multimedia assets represents a huge
opportunity for the Company’s current and future value proposition. As
highlighted in our press release earlier this week (PSYC Enters Strategic Partnership with Target Media to
Help Accelerate Audience and Revenue Growth Opportunities), the
Company has increased its year-over-year revenue earnings by nearly 94%. This
has primarily been a result of our acquisition of Technical 420 and On the Bids
last September which are platforms geared towards servicing companies in the
public markets. With Stock Day Media being a platform that is currently
producing sales-related revenue, we can reasonably anticipate for it to have an
immediate and positive impact on our bottom line right out of the gate and
hopefully build on this revenue growth in the months ahead. Additionally, the
board and I are also confident that we have structured this acquisition
prudently and in a manner that we believe is friendly and advantageous to our
shareholders and our ongoing operations budget by minimizing, to the extent
possible, dilution, as well as preserving our cash-on-hand by ensuring that
future cash payments are tied directly to the achievement of specific net
revenue-related milestones.We would also like to thank our new partners at
Target Media who played an instrumental role in helping to make this
acquisition possible through a strategic loan financing agreement that they
made available to the Company earlier this month.
This, in my opinion, is a clear example of
the tremendous value the Target Media team is actively delivering to PSYC and
how they are committed to working with us on helping to place the Company on
viable a path to becoming a formidable multimedia powerhouse.”
Stock Day Media Founder and CEO, Everett
Joly, shared his thoughts on joining the PSYC team: “Stock Day Media is excited
about the opportunity to join PSYC Corporation who has been a long-standing
client and recurring guest on our show over the past several years.
In the last few years alone, Mr. Flores and
his team have made wonderful progress with developing PSYC Corp into a leading
media authority for the psychedelics and cannabis sectors. And I believe that
by bringing our Stock Day Media platform into their business model, we are
helping to build off of this progress and are helping to create a more dynamic
and results-driven model that will ultimately contribute to and enhance the
monetization capabilities of every platform under their umbrella. I am also
looking forward to the opportunity that I believe this will present for us to
expand Stock Day Media’s existing business model and to focus on growth-related
strategies designed and intended for us to capture a larger and more
significant market share in the months ahead.”
Decibel
Cannabis Company Inc. (TSXV: DB) (OTCQB: DBCCF), announced that it has expanded its global
footprint by entering into a supply agreement to provide premium dried medical
cannabis flower to 4C LABS, a healthcare, technology, and pharmaceutical
company focused on virtual prescribing, pharmaceutical distribution and
clinical development in cannabis based medicinal products for human health in
the United Kingdom and Channel Islands (the "UK").
Key Highlights
●
Decibel to supply 4C LABS
with Qwest branded, craft-quality Medical Cannabis for distribution to UK
medical cannabis patients
●
Decibel to grant strain
exclusivity of rare and unique cultivars to be distributed by 4C LABS
●
3-year supply agreement
●
Initial shipment expected
before year end
●
Minimum purchase
commitments achieve exclusivity over certain genetics and QWEST brand in the UK
"We are excited to partner with 4C
LABS, a leading organization in the growing medical cannabis industry in the
UK, that echoes Decibel's commitment to quality and patient care. Not only will
this unlock a strong partnership and a new market for Decibel's craft cannabis
products, it also sets the stage for further growth into other European
markets," said Adam Coates, Chief Revenue Officer. "Decibel's success
with Qwest flower products in Canada and in Israel's medical market reinforces
the demand for premium cannabis products and the reputation we have built to
service that demand."
"4C LABS is building a patient focused
best-in-class product line for the UK & Channel Islands, the Qwest craft
flower line strengthens the top end of the 4C LABS product offerings. Decibel's
innovative craft quality Qwest flower products will fill an empty segment in
the UK market and bring a world class BC Cannabis product to UK patients,"
said Greg Dobbin, CEO 4C LABS. "Decibel's success in Canada, the most
competitive cannabis market in the world, is a product of hard work, innovation
and attention to detail, qualities that will resonate with UK patients."
Innocan
Pharma Corporation (CSE: INNO) (OTCQB: INNPF) announced the results of a clinical study
regarding the pain-relieving effects and safety of the Company's subcutaneous
liposomal CBD (Innocan's LPT platform) for dogs with osteoarthritis. Published
in the Frontiers in Veterinary Science Journal, under the research topic
"Use of Cannabis Derivatives in Veterinary Medicine". The Study
highlights that CBD plasma levels were detected for six weeks following a
single subcutaneous dose of Liposomal-CBD, causing minimal side effects and
effectively decreasing pain, leading to improved well-being in affected dogs.
In the study, six dogs with
naturally-occurring osteoarthritis, unresponsive to conventional medications,
were treated with a single injection of five mg/kg liposomal-CBD (in addition
to their routine medications). The subsequent observations spanned six weeks
and included measuring CBD plasma concentrations, blood work, collar activity
data, and evaluations of well-being and pain. The results were encouraging;
dogs exhibited a substantial drop in pain levels and an uptick in activity.
Key findings include:
●
Prolonged CBD detection in
the plasma with a peak concentration of 45.2 (17.8-72.5) ng/mL.
●
Significant decrease in
pain and increase in well-being for several weeks.
●
Significant increase in
activity (objectively measured) by the fifth and sixth weeks.
●
Minor swelling at the
injection site in five out of six dogs, which resolved within a few days
without any treatment.
The study underscores the effectiveness and
increased bioavailability of LPT-CBD tested as part of a multimodal pain
management in dogs with osteoarthritis. With the drug's plasma concentrations
detectable for six weeks and high exposure in terms of AUC (area under the
concentration-time curve), the research suggests that this liposomal
formulation could become a useful addition to pain management strategies for
improving the quality of life in dogs with osteoarthritis.
Read the full study on Frontiers in
Veterinary Science:
Frontiers | Therapeutic efficacy and pharmacokinetics of
liposomal-cannabidiol injection: a pilot clinical study in dogs with
naturally-occurring osteoarthritis (frontiersin.org)
MediPharm
Labs Corp. (TSX: LABS) (OTCQB: MEDIF) announced that Harvest Medicine's study
entitled, "Self-Reported Effects of Illness Severity, Depression and
Anxiety in Fibromyalgia Patients: A Large Retrospective Case Series" has
been published in the peer-reviewed American Journal of Endocannabinoid Medicine.
Harvest Medicine Inc. ("Harvest Medicine" or "HMED")
includes a medical clinic network, and is a wholly owned subsidiary of
MediPharm Labs.
The retrospective study was led by HMED and
reviewed data from 805 patients who indicated fibromyalgia as a primary reason
for seeking medical cannabis and had a minimum of one follow-up assessment. The
majority of patients (76.1%) reported using CBD oil, which aligns with the
current practice guidelines for authorising medical cannabis as an adjuvant
therapy for managing chronic pain.
The primary findings from the present study
include a significant reduction in all
three scores measuring depression, anxiety, and illness severity between
baseline and first follow-up.
●
75% of patients saw a
decrease in their self-reported illness severity, which may include chronic
pain, insomnia, and fatigue.
●
Anxiety scores were
improved in 22% of those patients reporting mild-moderate severity, and in 48%
of patients reporting severe anxiety.
●
27% of patients reporting
mild-medium depression noted a reduction in symptoms, while 48% of patients
reporting severe depression showed a reduction in PHQ-9 score.
The validated study data shows that medical
cannabis may play an effective role in the management of fibromyalgia and associated
symptoms of depression and anxiety, and that additional, similar studies are
recommended.
"Since 2017, Harvest Medicine's
primary objective is to improve the quality of patients' lives by providing
access to medical cannabis and offering the highest standard of medical care
with a scientifically informed approach" commented Barbara Vermeulen,
Director of Harvest Medicine. "We will continue to advocate for patients
to maintain access to physician guided consultations and education, with the
goal of reducing stigma among health care professionals and advancing patient
outcomes".
Details on the study can be viewed on American Journal of Endocannabinoids Website.
In other recent news reported by Marijuana Moment, earlier
this week the U.S. Department of Health and Human Services (HHS) officially
recommended that cannabis be moved from Schedule I to Schedule III under
federal law—a historic development that means the top health agency no longer
considers cannabis to be a drug with high abuse potential and no medical value.
After completing a scientific review into
cannabis under a directive from President Joe Biden last year,
HHS is now telling the Drug Enforcement Administration (DEA) that it believes
cannabis should be placed in Schedule III of the Controlled Substances Act
(CSA). The recommendation is not binding, and DEA has the final say, but the
scientific analysis combined with growing political support for cannabis reform
may well influence DEA to make the change.
“Following the data and science, HHS has
expeditiously responded to President Biden’s directive to HHS Secretary Becerra
and provided its scheduling recommendation for marijuana to the DEA on August
29, 2023,” an HHS spokesperson said in a statement to Marijuana Moment on
Wednesday. “This administrative process was completed in less than 11 months,
reflecting this department’s collaboration and leadership to ensure that a
comprehensive scientific evaluation be completed and shared expeditiously.”
Moving cannabis to Schedule III would also
unlock marijuana industry tax opportunities that are currently unavailable.
Following this announcement, U.S. Senate
leaders hailed the recommendation Wednesday as a first step toward easing
federal restrictions on cannabis.
Shares in Canopy Growth Corp. (NASDAQ:CGC) rose more than 28 per cent Thursday,
after climbing nine per cent Wednesday. Tilray
Brands, Inc.(NASDAQ:TLRY) shares also saw a rise, almost 11
per cent, after its stock rose more than 10 per cent Wednesday, and shares of Aurora Cannabis Inc. (NASDAQ:ACB) rose almost five per cent.
While this is optimistic news at the moment
for the cannabis sector, there is one issue when it comes to cannabis as well
as drug studies in general in the current medical and corporate world; almost
all of them are biassed and therefore unreliable.
I wouldn’t go as far as to say there is
falsified data in any of either the pro or anti cannabis studies that circulate
the web on a weekly basis, but the issue is, oppositional studies exist
alongside one another at all times.
This week alone I saw several articles
discussing studies showing that cannabis use is leading to an increase in
schizophrenia and cannabis use disorder, while at the same I saw articles come
out claiming the opposite.
Below are links to a few examples to get an
idea of what I’m talking about.
How marijuana impacts pain, sleep, anxiety and more,
according to the latest science | CNN
Young people, pregnant women and drivers should avoid
cannabis – study | Cannabis | The Guardian
Study: Young MJ Consumers With Psychosis Risk Saw Symptom
Improvement | High Times
The issue is, both studies seem reliable at
first glance, but upon further scrutiny, both sides of the argument prove to be
biassed.
The issue stems from corporate owned
“medical journals”.
Certain Pharmaceutical companies own
different medical journals to add legitimacy to their products, and this is a
well known fact in the world of medicine and drug development. As cannabis
continues to expand its reach the same is now true for the cannabis industry.
There are still seemingly reputable sources
such as Johns Hopkins, but even they have produced opposing studies and
findings.
Even anecdotal evidence is hard to take
into account as the internet has become ripe with false accounts, false information
and opposing narratives.
What seems to be close to the truth is that
cannabis is a serious competitor to traditional pharmaceuticals on the market,
whether we are looking at pain management drugs, anxiety or depression drugs or
cancer drugs. What also seems true is that the cannabis industry and research
in general regarding micro-cannabinoids is still in its infancy compared to
other substances currently available through the traditional pharma/medical
model.
The problem with cannabis and opposing
studies is the same problem we see for nearly all medicine on the market today.
I don’t even want to get started on vaccines.
So moving forward, especially as we see the
pharmaceutical industry begin to hedge their bets and invest in synthetic
cannabinoids, which are a nightmare and should be tossed aside, how does
cannabis avoid going down the same path of every other medical product on the
market today?
No one wants to see side effect warnings
for cannabis catch up to pharmaceuticals in 5 years, but based on the current
trajectory of things, that isn’t outside the realm of possibility,
So while I do still believe overall in the
benefits of cannabis, mainly due to my lived experience and interactions with
hundreds of people who have explained their stories of how cannabis use
massively improved their quality of life and overall health, it is hard not to
look at how business is slowly infecting cannabis with all the mistakes of the
past.
Investor ideas reminds all listeners to
read our disclaimers and disclosures on the Investorideas.com website and that
this podcast is not an endorsement to buy products or services or securities.
Investors are reminded all investment involves risk and possible loss of
investment.
To hear more Investorideas.com
podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also
available on iTunes ( Apple Podcasts) ,
Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Podcasts and most audio platforms
available.
About
Investorideas.com - Big Investing Ideas
Investorideas.com is a platform for investing ideas. We
publish breaking stock news, stock research, guest posts and create original
top rated investing podcasts, plus sector tag articles featuring up and coming
companies and industry leaders. Investor
Idea’s original branded content includes the Crypto
Corner Podcast , Play by Play Sports Podcast , Cannabis
News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast
and the AI Eye Podcast. We
also create free investor stock directories for AI and tech, biotech, cannabis,
cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas,
sports and water.
Public companies within the sectors we cover can use our
news publishing and content creation services to help tell their story to interested
investors.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing
your news release and our other news services on the Investorideas.com
newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except
where permissible by law. Our site does not possess, distribute, or sell
cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook
https://www.facebook.com/Investorideas
Follow us on YouTube
https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Thursday, 31 August 2023
Hemp Stock News: Hempacco (NASDAQ: HPCO) Receives $1M Purchase Orders for 'Dogg lbs' Gummies
Hemp Stock News: Hempacco (NASDAQ: HPCO) Receives $1M Purchase Orders for 'Dogg lbs' Gummies: Hemp Stock News: Hempacco (NASDAQ: HPCO) Receives $1M Purchase Orders for 'Dogg lbs' Gummies
Tuesday, 29 August 2023
Cannabis Stock News: PharmaCielo (TSXV: PCLO) (OTCQX: PCLOF) Announces Q2 2023 Financial Results
Cannabis Stock News: PharmaCielo (TSXV: PCLO) (OTCQX: PCLOF) Announces Q2 2023 Financial Results: Cannabis Stock News: PharmaCielo (TSXV: PCLO) (OTCQX: PCLOF) Announces Q2 2023 Financial Results
Psilocybin Stock News: Red Light Holland (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) Reports First Quarter 2024 Results
Psilocybin Stock News: Red Light Holland (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) Reports First Quarter 2024 Results: Psilocybin Stock News: Red Light Holland (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) Reports First Quarter 2024 Results
Subscribe to:
Posts (Atom)
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ... -
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Dixie Brands (CSE: $DIXI_U.C) (OTC: $DXBRF), Khiron Life Sciences (T... -
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...